Switch to:
More From Other Websites
See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc. Sep 12 2017
What Analysts Recommend for BioMarin Pharmaceuticals in September Sep 11 2017
Sarepta Therapeutics Chart Patterns Look Good Sep 07 2017
Sarepta's Golodirsen Positive in DMD Study, Shares Soar Sep 07 2017
[$$] Sarepta: Turbocharge Returns With Options Sep 07 2017
One Worry Off the Table (Until December) Sep 07 2017
Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Myriad Genetics Sep 07 2017
Sarepta’s positive trial results for new DMD treatment could reopen rare disease drug controversy Sep 07 2017
What Happened in the Stock Market Today Sep 06 2017
This Controversial Biotech May Yet Defy Its Skeptics Sep 06 2017
Can you trust Facebook? It's in the Blitz Sep 06 2017
We May Soon Learn Just How Flexible Scott Gottlieb's FDA Is Sep 06 2017
Is There Now An Opportunity In Sarepta Therapeutics Inc (SRPT)? Sep 06 2017
​Why Sarepta’s latest trial data may presage another FDA controversy Sep 06 2017
Why Sarepta Therapeutics Stock Is Rising Today Sep 06 2017
[$$] Soaring Sarepta Can Continue to Stay Hot Sep 06 2017
CEO defends $300,000-per-year cost for a drug for a rare form of muscular dystrophy Sep 06 2017
Stocks to Watch: Hewlett Packard Enterprise, Fiat Chrysler, Exxon Mobil, Sarepta Therapeutics, G-III... Sep 06 2017
Shares of drugmaker that targets gene mutations soar after positive study results Sep 06 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK